FIRST-IN-MAN STUDY OF 4SC-202, A NOVEL ORAL HDAC INHIBITOR IN PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES; (TOPAS STUDY)

被引：0
|
作者：
von Tresckow, B. [1 ]
Goebeler, M. E. [2 ]
Sayehli, C. [2 ]
Gundermann, S. [2 ]
Eichenauer, D. [1 ]
Aulitzky, W. [3 ]
Bacchus, L. [3 ]
Igel, S. [4 ]
Schwab, M. [4 ]
Sasse, S. [1 ]
Hauns, B. [5 ]
Mais, A. [5 ]
Hentsch, B. [5 ]
Kohlhof, H. [5 ]
Krauss, R. [5 ]
Krauss, B. [5 ]
Baumgartner, R. [5 ]
Vitt, D. [5 ]
Engert, A. [1 ]
机构：
[1] Univ Hosp Cologne, Cologne, Germany
[2] Univ Hosp Wuerzburg, Wurzburg, Germany
[3] Robert Bosch Krankenhaus, Stuttgart, Germany
[4] Dr Margarte Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[5] 4SC AG, Planegg Martinsried, Germany
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1858
引用
收藏
页码：711 / 711
页数：1
相关论文
共 50 条
  • [31] Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
    Deenen, Maarten J.
    Klumpen, Heinz-Josef
    Richel, Dick J.
    Sparidans, Rolf W.
    Weterman, Mariette J.
    Beijnen, Jos H.
    Schellens, Jan H. M.
    Wilmink, Johanna W.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1557 - 1565
  • [32] Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
    LoRusso, PM
    Adjei, AA
    Varterasian, M
    Gadgeel, S
    Reid, J
    Mitchell, DY
    Hanson, L
    DeLuca, P
    Bruzek, L
    Piens, J
    Asbury, P
    Van Becelaere, K
    Herrera, R
    Sebolt-Leopold, J
    Meyer, MB
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5281 - 5293
  • [33] Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
    Maarten J. Deenen
    Heinz-Josef Klümpen
    Dick J. Richel
    Rolf W. Sparidans
    Mariette J. Weterman
    Jos H. Beijnen
    Jan H. M. Schellens
    Johanna W. Wilmink
    Investigational New Drugs, 2012, 30 : 1557 - 1565
  • [34] A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
    van Bussel, Mark T. J.
    Awada, Ahmad
    de Jonge, Maja J. A.
    Mau-Sorensen, Morten
    Nielsen, Dorte
    Schoffski, Patrick
    Verheul, Henk M. W.
    Sarholz, Barbara
    Berghoff, Karin
    El Bawab, Samer
    Kuipers, Mirjam
    Damstrup, Lars
    Diaz-Padilla, Ivan
    Schellens, Jan H. M.
    BRITISH JOURNAL OF CANCER, 2021, 124 (04) : 728 - 735
  • [35] Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
    Kuebler, Hubert
    Scheel, Birgit
    Gnad-Vogt, Ulrike
    Miller, Kurt
    Schultze-Seemann, Wolfgang
    vom Dorp, Frank
    Parmiani, Giorgio
    Hampel, Christian
    Wedel, Steffen
    Trojan, Lutz
    Jocham, Dieter
    Maurer, Tobias
    Rippin, Gerd
    Fotin-Mleczek, Mariola
    von der Muelbe, Florian
    Probst, Jochen
    Hoerr, Ingmar
    Kallen, Karl-Josef
    Lander, Thomas
    Stenzl, Arnulf
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3
  • [36] A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
    Mark T. J. van Bussel
    Ahmad Awada
    Maja J. A. de Jonge
    Morten Mau-Sørensen
    Dorte Nielsen
    Patrick Schöffski
    Henk M. W. Verheul
    Barbara Sarholz
    Karin Berghoff
    Samer El Bawab
    Mirjam Kuipers
    Lars Damstrup
    Ivan Diaz-Padilla
    Jan H. M. Schellens
    British Journal of Cancer, 2021, 124 : 728 - 735
  • [37] A phase I, dose-escalation, multi-center study of PFK-158 in patients with advanced solid malignancies explores a first-in-man inhbibitor of glycolysis.
    Redman, Rebecca A.
    Pohlmann, Paula Raffin
    Kurman, Michael R.
    Tapolsky, Gilles
    Chesney, Jason Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies.
    Papandreou, CN
    Pagliaro, L
    Millikan, R
    Daliani, D
    Herrmann, J
    Hong, Y
    Smith, M
    Adams, J
    Elliot, P
    Lightcap, E
    McCormack, T
    Pien, C
    Newman, R
    Logothetis, CJ
    CLINICAL CANCER RESEARCH, 1999, 5 : 3730S - 3730S
  • [39] A phase I/II study of the oral mTOR inhibitor RAD001 in patients with advanced Hematologic malignancies
    Yee, K
    O'Brien, S
    Wierda, W
    Thomas, D
    Kurzrock, R
    Fayad, L
    Hagemeister, F
    Goy, A
    Cortes, J
    Prestifilippo, J
    Szatrowski, T
    Kantarjian, H
    Giles, F
    JOURNAL OF IMMUNOTHERAPY, 2004, 27 (06) : S35 - S35
  • [40] Phase I Study of the Oral Histone Deacetylase Inhibitor SB939 In Patients with Advanced Hematologic Malignancies
    Garcia-Manero, Guillermo
    Chuah, Charles
    Wilding, George
    Chang, Julie
    Verstovsek, Srdan
    Faderl, Stefan
    Kantarjian, Hagop M.
    Ethirajulu, Kantharaj
    Zhu, Joy
    BLOOD, 2010, 116 (21) : 1349 - 1349
12345